The DOI matches its Crossref record.
The Cancer Immunotherapy Revolution
Abstract
![Figure][1] The new generation of cancer immunotherapies includes ways to engineer patients' own immune cells to kill their cancer and patient-specific neoantigen vaccines. This image alludes to the hope of personalized therapy tailored to each patient. ILLUSTRATION: DANIEL HERTZBERG Cancer immunotherapy—the science of mobilizing the immune system to kill cancer—has been pursued for more than a century. Yet only recently has this powerful strategy finally taken center stage in mainstream oncology. The past few years have seen unprecedented clinical responses, rapid drug development, and first-in-kind approvals from the U.S. Food and Drug Administration. Reports of terminal cancer patients defying the odds and achieving complete remissions are accumulating. These success stories are the culmination of decades of painstaking research by pioneering scientists and physicians. Newly approved immunotherapies include drugs that can manipulate components of the immune system and methods to genetically engineer patients' own T lymphocytes to recognize and attack their tumors. Researchers are racing to expand the use of immunotherapy to benefit more cancer patients. But it remains unclear why only a subset of individuals respond to treatment and how to better achieve sustained remissions. Hundreds of clinical trials are under way to see whether improved responses can be attained by combination therapy approaches. Unraveling the cellular and molecular basis of treatment resistance should facilitate rational design of new mechanism-based studies. Advances in genome sequencing are identifying predictive biomarkers and facilitating the design of personalized vaccines that target patient-specific tumor neoantigens. These lines of research, along with growing evidence that the gut microbiome plays a defining role in immunotherapy response, are charting innovative paths toward truly personalized medicine. [1]: pending:yes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Kuerban, K., Gao, X., Zhang, H., Liu, J., Dong, M., Wu, L., Ye, R., Feng, M., & Ye, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.002 · Cited by 277
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 267
Creatine metabolism: energy homeostasis, immunity and cancer biology
Kazak, L., & Cohen, P. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0365-5 · Cited by 265
Wei, B., Pan, J., Yuan, R., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00209 · Cited by 265
Metadata
- Authors
- Kelly, P. N.
- Venue
- Science
- Published
- 2018-03-23
- Volume
- 359
- Issue
- 6382
- Pages
- 1344-1345
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2791653121
- Cited by
- 159
- References
- 0
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cancer Immunotherapy Revolution. https://app.cochat.ai/papers/10.1126/science.359.6382.1344
- The paper
- Kelly, P. N. (2018). The Cancer Immunotherapy Revolution. Science. https://doi.org/10.1126/science.359.6382.1344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.